Please login to the form below

Not currently logged in
Email:
Password:

bacterial infections

This page shows the latest bacterial infections news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more

Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more

The government is giving £20m to support scientific research around the world to develop new vaccines and alternatives-to-antibiotics against drug-resistant bacterial infections in humans.

Latest news

More from news
Approximately 2 fully matching, plus 64 partially matching documents found.

Latest Intelligence

  • Another lost decade for research? Another lost decade for research?

    Such technologies, which allow doctors to diagnose bacterial from viral infections or distinguish between different bacteria, could lead to personalised treatments and avoid unnecessary prescription of antibiotics. ... In terms of research focus, the

  • Pharma deals in September 2015 Pharma deals in September 2015

    300. AstraZeneca. US Dept of Health &Human Services. Combining antibiotics to tackle multi-drug resistant bacterial infections.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Licence. 201. GlycoVaxyn/ GSK. Conjugation platform plus early stage vaccines against bacterial infections such as pneumonia, Pseudomonas, S.

  • Curbing the rise of drug resistance Curbing the rise of drug resistance

    The global economic impact of anti-microbial resistance forecasts that, if unchecked, drug-resistant infections could cost the world 10 million extra deaths a year and cost up to $100tn by ... According to Professor Dame Sally Davies, chief medical

  • Cubist: Meeting the challenge in antibiotics Cubist: Meeting the challenge in antibiotics

    We estimate that more than 30, 000 people per year die in Europe alone due to bacterial infections and hospital-acquired infections are in particular a problem because that is where ... Hospital-acquired bacterial pneumonia (HABP)/ventilator-associated

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Nabriva Therapeutics appoints chief medical officer Nabriva Therapeutics appoints chief medical officer

    Nabriva Therapeutics, a biopharma focused on treating bacterial infections, has appointed a new chief medical officer in the form of Jennifer Schranz. ... we continue to advance the legamulin programme toward a potential approval for the treatment of

  • Nabriva Therapeutics appoints new chief commercial officer Nabriva Therapeutics appoints new chief commercial officer

    Bacterial infections focussed Nabriva Therapeutics has appointed Francesco Maria Lavino as its chief commercial officer ahead of the group’s phase III clinical trial for lefamulin - a potential new treatment for ... I am looking forward to working with

  • Dr Engelbert Tjeenk Willink joins Allecra Therapeutics Dr Engelbert Tjeenk Willink joins Allecra Therapeutics

    He said: “Allecra is a dynamic company with the potential to make a significant impact on the growing and widespread epidemic of drug-resistant bacterial infections. ... Hooftman’s new role will see him focus on combating multi drug-resistant

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics